Parent Page: Directory id: 22535 Active Page: Detailsid:23325



Taha Al-Juaishi, MD
Internal Medicine

Taha Al-Juhaishi, MD

Assistant Professor

Transplant and Cellular Therapy Program



  • Stem Cell Transplantation and Cellular Therapies University of Texas MD Anderson Cancer Center
    Houston, TX
  • Hematology/Oncology Virginia Commonwealth University
    Richmond, VA


  • Internal Medicine Virginia Commonwealth University
    Richmond, VA

Medical School

  • Doctor of Medicine Weill Cornell Medicine

Board Certification(s):

  • Internal Medicine
  • Medical Oncology
  • Hematology

Clinical/Research Interests:

  • Stem cell transplantation and cellular therapies
  • Cancer outcomes research
  • Early drug development in lymphoma and leukemia

Select Publications:

  1. Al-Juhaishi T, Ahmed S. CAR-T in B-Cell Lymphomas: The Past, Present, and Future. Clin Lymphoma Myeloma Leuk. 2021 Oct 15:S2152-2650(21)02383-1. doi: 10.1016/j.clml.2021.10.003.
  2. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, et al. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma. 2021 Oct 22:1-12. doi: 10.1080/10428194.2021.1992763. Epub ahead of print
  3. Al-Juhaishi T, Al-Kindi SG. Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol. 2021 Jul 26:S0167-5273(21)01188-8. doi: 10.1016/j.ijcard.2021.07.043
  4. Al-Juhaishi T, Ahmed S. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. Curr Hematol Malig Rep. 2021 Feb 25. doi: 10.1007/s11899-021-00615-7
  5. Koebley SR, Mikheikin A, Leslie K, Guest D, McConnell-Wells W, Lehman JH, Al Juhaishi T, Zhang X, Roberts CH, Picco L, Toor A, Chesney A, Reed J. Digital Polymerase Chain Reaction Paired with High-Speed Atomic Force Microscopy for Quantitation and Length Analysis of DNA Length Polymorphisms. ACS Nano. 2020 Nov 10. doi: 10.1021/acsnano.0c05897.   
  6. Neuwelt A, Al-Juhaishi T, Davila E, Haverkos B. Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas. Blood Adv. 2020;4(17):4256-4266.
  7. Al-Juhaishi T, Mckay J, Sindel A, Yazbeck V. Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020;21(6):653-661.
  8. Sindel A, Al-Juhaishi T, Yazbeck V. Marginal Zone Lymphoma: State-of-the-Art Treatment. Curr Treat Options Oncol. 2019 Dec 5;20(12):90. doi: 10.1007/s11864-019-0687-5.
  9. Al-Juhaishi T, Khurana A, Shafer D. Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks. Best Pract Res Clin Haematol. 2019 Mar;32(1):47-53. doi: 10.1016/j.beha.2019.02.008.
  10. Al-Juhaishi T, Yazbeck V. Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: does one size fit all? Expert Opin Pharmacother. 2019 May;20(7):773-775. doi: 10.1080/14656566.2019.1582643.